Antibody-drug conjugates (ADCs), viral vectors, and lipid nanoparticles (LNPs) share one defining constraint: the manufacturing infrastructure to produce them at clinical and commercial scale is scarce, technically specialized, and concentrated in a small number of organizations. Each modality requires different facility designs, containment standards, and regulatory pathways. In the United States, that combination of scarcity and complexity has made domestic CDMO capacity for these modalities a genuine bottleneck.
The ADC contract manufacturing and development market was valued at USD 11.08 billion in 2026 and is projected to reach USD 29.65 billion by 2035, according to a February 2026 report by Towards Healthcare Research & Consulting, reflecting an 11.56 percent compound annual growth rate driven by oncology demand and the pharmaceutical industry's preference for outsourcing complex manufacturing.
Lonza announced on November 3, 2026, that it had signed a definitive agreement to acquire five CDMO sites in the United States from Merck KGaA, Darmstadt, Germany. The transaction, valued at a total enterprise figure in the low- to mid-triple-digit millions Swiss francs, adds bioconjugation, high-potency payload-linker, viral vector, and LNP manufacturing to Lonza's existing US network, more than doubling its US footprint from four to nine sites. The deal transfers approximately 1,100 employees to Lonza, bringing its US workforce above 6,000.
Lonza's five acquired sites span ADC, viral vector, and LNP manufacturing
Each of the five acquired sites addresses a distinct step in the production of complex biologics, covering capabilities that Lonza's existing US network did not fully include:
- St. Louis, Missouri (bioconjugation): ADC and bioconjugate manufacturing, from process development through commercial scale
- Madison and Verona, Wisconsin (payload-linkers): High-potency cytotoxic payload synthesis under specialized HPAPI containment
- Carlsbad, California (viral vectors): End-to-end gene therapy manufacturing, including aseptic fill-finish
- Indianapolis, Indiana (LNPs and liposomes): Lipid nanoparticle, liposome, and PEGylated protein manufacturing with aseptic fill-finish, supporting mRNA and nucleic acid delivery programs
The site combination is notable for addressing complementary steps within the ADC manufacturing chain. ADCs require antibody production, high-potency payload synthesis, chemical conjugation, and drug-product fill-finish: four process steps that most contract manufacturers do not offer under a single network. Few CDMOs offer all four steps under one network, and this acquisition closes that gap in the US.
Lonza projects the acquired sites will contribute around CHF 250 million in sales in full-year 2028 at a CORE EBITDA margin below the company's current group level. The sites are expected to reach Lonza's future group margin level by the mid-2030s as capacity utilization and further targeted investments increase.
Wolfgang Wienand, CEO of Lonza, cited the demand environment driving the deal. "With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply," Wienand said.
Why end-to-end complex biologics manufacturing remains a bottleneck
Full-chain biologics manufacturing requires distinct containment, regulatory expertise, and capital at each production step and few US organizations have built all of them. For ADCs specifically, the number of US programs seeking manufacturing partners now outpaces the facilities capable of handling the full process chain. For viral vectors, the acute shortage of 2019 to 2021 has eased, but analysts project continued pressure as more gene therapy programs move to commercial scale and require fill-finish volumes that earlier clinical-stage facilities cannot support.
Each modality class in the acquisition carries different technical demands, and US capacity constraints differ across all three:
Modality | Core manufacturing requirements | US CDMO capacity availability | Acquired Lonza sites |
|---|---|---|---|
Antibody-drug conjugates | Antibody production, high-potency payload synthesis (HPAPI containment), bioconjugation, aseptic fill-finish | Limited end-to-end domestic providers; payload-linker synthesis is the scarcest step | St. Louis (conjugation); Madison and Verona (payload-linker) |
Viral vectors (AAV, lentivirus) | Specialized bioreactors, high-purity upstream processing, aseptic fill-finish | Capacity expanded post-2021 shortage; fill-finish at commercial scale remains a bottleneck | Carlsbad (end-to-end, including fill-finish) |
Lipid nanoparticles and liposomes | Precision lipid formulation, nucleic acid encapsulation, cryoprotection, fill-finish | Growing capacity driven by mRNA demand; US domestic providers expanding post-2020 | Indianapolis (LNP, liposome, PEGylated protein, fill-finish) |
With its antibody manufacturing infrastructure in Visp, Switzerland and ongoing readiness investment in Vacaville, California, Lonza is now positioned to offer clinical-through-commercial coverage across the full ADC value chain without requiring a customer to switch manufacturing partners mid-program.
For Merck KGaA, the divestiture reflects a strategic simplification of its Life Science segment. Merck KGaA is refocusing toward its core scientific leadership, a direction consistent with its June 2026 agreement to acquire Bio-Techne, a US-based provider of analytical technologies, for USD 11.3 billion. Kai Beckmann, Chair of the Executive Board and Group CEO of Merck KGaA, described the rationale. "A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership and make us an even stronger partner for our customers," Beckmann said. "Our CDMO teams have built a strong foundation through their expertise and commitment."
CDMO consolidation in 2025–26: capability over scale
This acquisition sits within a broader wave of CDMO consolidation that accelerated through 2025 and into 2026. A July 2026 report by Alira Health found that the global biologics CDMO market grew to USD 23.2 billion in 2025, with specialized capability overtaking raw scale as the primary competitive differentiator; the same report tracked 29 M&A transactions in 2025, with manufacturing capability central to nearly 80 percent of deals. A separate August 2026 industry analysis found CDMO deal value and volume in early 2026 running roughly double the same period in 2025, driven by onshoring pressure, evolving trade policies, and demand for specialized manufacturing that generalist capacity cannot address.
Pharma-to-CDMO asset transfers have become a recurring structural pattern: companies divesting manufacturing sites that no longer fit their core strategy, with CDMO acquirers consolidating those assets into broader service networks. In the first quarter of 2026 alone, Bristol Myers Squibb and Sanofi each transferred US manufacturing facilities to CDMO partners. The Lonza-Merck KGaA transaction covers five sites across multiple modality classes, but follows the same logic: pharmaceutical companies prefer to concentrate capital on discovery and clinical development while CDMOs absorb the manufacturing infrastructure.
For CDMOs, scale and modality breadth determine customer retention across a drug's lifecycle. A CDMO that takes a biologic from Phase 1 through commercial launch without a technology transfer to a second manufacturer holds a significant competitive advantage, since each handoff creates supply risk. By covering clinical development through commercial manufacturing across three modality classes, the Lonza acquisition targets exactly that integrated position in the US market.
Lonza-Merck KGaA CDMO deal: integration timeline and outlook
Transaction closing is expected in mid-2027, subject to regulatory and closing conditions, with the five acquired sites continuing to operate independently until then. Lonza confirmed its 2026 financial outlook and Organic Growth Model remain unchanged, and projects the acquired network will contribute around CHF 250 million in annual sales by full-year 2028 before reaching group margin levels by the mid-2030s. Whether the deal reshapes Lonza's competitive position in US complex biologics manufacturing depends on integration execution: sustaining customer continuity across five sites and three modality classes is the operational challenge behind the strategic rationale.
This article is based on a press release issued by Lonza and was produced under Drug Discovery News' AI Editorial Guidelines.
